Literature DB >> 31492539

Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology.

Tessnim R Ahmad1, Lee-May Chen2, Jocelyn S Chapman2, Lee-Lynn Chen3.   

Abstract

OBJECTIVE: To compare postoperative outcomes by primary payer status for patients with gynecologic malignancies.
METHODS: We retrospectively reviewed patients who underwent elective surgery for gynecologic malignancies between 2015 and 2019. Patient outcomes were compared by payer status using logistic regression. Sociodemographic and clinical covariates were selected a priori and included age, American Society of Anesthesiologists physical status classification, body mass index, smoking status, malignancy site, surgery type, race, estimated income, marital status, and medical interpreter requirement.
RESULTS: A total of 1894 patients comprised the study sample. In the multivariate model, compared to patients with private insurance, Medicaid and Medicare patients were more likely to mobilize >24 h after surgery (OR 1.9, p < 0.05 and OR 3.2, p < 0.001, respectively), to require ICU admission (OR 4.0, p < 0.05 and OR 5.0, p < 0.05, respectively), and to have longer lengths of stay (OR 1.8, p < 0.05 and OR 2.2, p < 0.001, respectively). Medicaid patients were also more likely to have higher total hospital costs (OR 1.7, p < 0.05). Payer status was not associated with postoperative pain, postoperative opiate use, or 30-day readmission rates.
CONCLUSIONS: Medicaid and Medicare payer status are associated with worse postoperative outcomes in patients with gynecologic malignancies. The poor outcomes of Medicaid patients - a cohort defined by limited income - are noteworthy. The etiology is likely multifactorial, arising from a complex interplay of factors ranging from system issues such as access to care to the unique health status of a population bearing a high burden of disease and socioeconomic adversity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Health disparities; Medicaid; Medicare; Outcomes; Payer status

Mesh:

Year:  2019        PMID: 31492539     DOI: 10.1016/j.ygyno.2019.08.013

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Impact of Insurance Status on Oncologic and Perioperative Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Authors:  David N Hanna; Muhammad O Ghani; Andrew Hermina; Alexander Mina; Christina E Bailey; Kamran Idrees; Deepa Magge
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 4.339

2.  ASO Author Reflections: Disparate Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Based on Insurance Status.

Authors:  David N Hanna; Deepa Magge
Journal:  Ann Surg Oncol       Date:  2021-08-28       Impact factor: 4.339

3.  Patient Expectations for Symptomatic Improvement before Cubital Tunnel Release.

Authors:  Miranda J Rogers; Chinelo C Agwuncha; Nikolas H Kazmers
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-03-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.